Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viropharma Picovir Oral Contraceptive Study Data Expected This Summer

Executive Summary

Viropharma expects to have data from a Phase I drug interaction study of oral contraceptives and Picovir (pleconaril) in two to four months

You may also be interested in...



Schering To Fund Picovir Studies Under Development Deal With ViroPharma

Schering-Plough will decide whether to fund additional development of ViroPharma's Picovir after assessing preclinical and Phase I data for an intranasal formulation of the common cold treatment in mid-2004

Schering To Fund Picovir Studies Under Development Deal With ViroPharma

Schering-Plough will decide whether to fund additional development of ViroPharma's Picovir after assessing preclinical and Phase I data for an intranasal formulation of the common cold treatment in mid-2004

Aventis DiaPep277 Phase III Discussion Focuses On Endpoint; Picovir Dropped

Aventis/Peptor DiaPep277 will enter Phase III trials following agreement with FDA on appropriate clinical endpoints for the diabetes agent

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS039561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel